The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis

Jie Fu,1 Lilei Peng,2 Xiaogang Li1 1Department of Neurology, 2Department of Neurosurgery, The Affiliated Hospital of Luzhou Medical College, Luzhou, People’s Republic of China Objective: Vortioxetine is a novel antidepressant approved for the treatment of major depressive disorder by the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fu J, Peng LL, Li XG
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	vortioxetine placebo generalized anxiety disorder meta-analysis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/45ffe0a13c884ef29dfe92ae63183fce
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:45ffe0a13c884ef29dfe92ae63183fce
record_format	dspace
spelling	oai:doaj.org-article:45ffe0a13c884ef29dfe92ae63183fce2021-12-02T01:25:47ZThe efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis1178-2021https://doaj.org/article/45ffe0a13c884ef29dfe92ae63183fce2016-04-01T00:00:00Zhttps://www.dovepress.com/the-efficacy-and-safety-of-multiple-doses-of-vortioxetine-for-generali-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Jie Fu,1 Lilei Peng,2 Xiaogang Li1 1Department of Neurology, 2Department of Neurosurgery, The Affiliated Hospital of Luzhou Medical College, Luzhou, People’s Republic of China Objective: Vortioxetine is a novel antidepressant approved for the treatment of major depressive disorder by the US Food and Drug Administration in September 2013. This meta-analysis assessed the efficacy and safety of different doses of vortioxetine for generalized anxiety disorder of adults.Methods: PubMed, Cochrane Library, PsycINFO, and Clinical Trials databases were searched from 2000 through 2015. The abstracts of the annual meetings of the American Psychiatric Association and previous reviews were searched to identify additional studies. The search was limited to individual randomized controlled trials (RCTs), and there was no language restriction. Four RCTs met the selection criteria. These studies included 1,843 adult patients. Results were expressed as odds ratios (ORs) and 95% confidence intervals (CIs). The data were pooled with a random-effects or fixed-effects model.Results: The results showed that multiple doses (2.5, 5, and 10 mg/d) of vortioxetine did not significantly improve the generalized anxiety disorder symptoms compared to placebo (OR=1.16, 95% CI=0.84–1.60, Z=0.89, P=0.38; OR=1.41, 95% CI=0.82–2.41, Z=1.25, P=0.21; OR=1.05, 95% CI=0.76–1.46, Z=0.32, P=0.75, respectively). We measured the efficacy of 2.5 mg/d vortioxetine compared to 10 mg/d, and no significant differences were observed. The common adverse effects included nausea and headache. With increased dose, nausea was found to be more frequent in the vortioxetine (5 and 10 mg/d) group (OR=2.99, 95% CI=1.31–6.84, Z=2.60, P=0.009; OR=2.80, 95% CI=1.85–4.25, Z=4.85, P<0.00001, respectively), but no significant differences were observed for headache.Conclusion: The results showed no significant improvement in the treatment of generalized anxiety disorder for vortioxetine compared to placebo, and nausea was more frequent with higher doses. So the current evidences do not support using vortioxetine for the treatment of generalized anxiety disorder. Few RCTs were included in our meta-analysis, and more studies are needed to verify our results in the future. Keywords: vortioxetine, placebo, generalized anxiety disorder, meta-analysisFu JPeng LLLi XGDove Medical Pressarticlevortioxetineplacebogeneralized anxiety disordermeta-analysisNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2016, Iss Issue 1, Pp 951-959 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	vortioxetine placebo generalized anxiety disorder meta-analysis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	vortioxetine placebo generalized anxiety disorder meta-analysis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Fu J Peng LL Li XG The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis
description	Jie Fu,1 Lilei Peng,2 Xiaogang Li1 1Department of Neurology, 2Department of Neurosurgery, The Affiliated Hospital of Luzhou Medical College, Luzhou, People’s Republic of China Objective: Vortioxetine is a novel antidepressant approved for the treatment of major depressive disorder by the US Food and Drug Administration in September 2013. This meta-analysis assessed the efficacy and safety of different doses of vortioxetine for generalized anxiety disorder of adults.Methods: PubMed, Cochrane Library, PsycINFO, and Clinical Trials databases were searched from 2000 through 2015. The abstracts of the annual meetings of the American Psychiatric Association and previous reviews were searched to identify additional studies. The search was limited to individual randomized controlled trials (RCTs), and there was no language restriction. Four RCTs met the selection criteria. These studies included 1,843 adult patients. Results were expressed as odds ratios (ORs) and 95% confidence intervals (CIs). The data were pooled with a random-effects or fixed-effects model.Results: The results showed that multiple doses (2.5, 5, and 10 mg/d) of vortioxetine did not significantly improve the generalized anxiety disorder symptoms compared to placebo (OR=1.16, 95% CI=0.84–1.60, Z=0.89, P=0.38; OR=1.41, 95% CI=0.82–2.41, Z=1.25, P=0.21; OR=1.05, 95% CI=0.76–1.46, Z=0.32, P=0.75, respectively). We measured the efficacy of 2.5 mg/d vortioxetine compared to 10 mg/d, and no significant differences were observed. The common adverse effects included nausea and headache. With increased dose, nausea was found to be more frequent in the vortioxetine (5 and 10 mg/d) group (OR=2.99, 95% CI=1.31–6.84, Z=2.60, P=0.009; OR=2.80, 95% CI=1.85–4.25, Z=4.85, P<0.00001, respectively), but no significant differences were observed for headache.Conclusion: The results showed no significant improvement in the treatment of generalized anxiety disorder for vortioxetine compared to placebo, and nausea was more frequent with higher doses. So the current evidences do not support using vortioxetine for the treatment of generalized anxiety disorder. Few RCTs were included in our meta-analysis, and more studies are needed to verify our results in the future. Keywords: vortioxetine, placebo, generalized anxiety disorder, meta-analysis
format	article
author	Fu J Peng LL Li XG
author_facet	Fu J Peng LL Li XG
author_sort	Fu J
title	The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis
title_short	The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis
title_full	The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis
title_fullStr	The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis
title_full_unstemmed	The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis
title_sort	efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/45ffe0a13c884ef29dfe92ae63183fce
work_keys_str_mv	AT fuj theefficacyandsafetyofmultipledosesofvortioxetineforgeneralizedanxietydisorderametaanalysis AT pengll theefficacyandsafetyofmultipledosesofvortioxetineforgeneralizedanxietydisorderametaanalysis AT lixg theefficacyandsafetyofmultipledosesofvortioxetineforgeneralizedanxietydisorderametaanalysis AT fuj efficacyandsafetyofmultipledosesofvortioxetineforgeneralizedanxietydisorderametaanalysis AT pengll efficacyandsafetyofmultipledosesofvortioxetineforgeneralizedanxietydisorderametaanalysis AT lixg efficacyandsafetyofmultipledosesofvortioxetineforgeneralizedanxietydisorderametaanalysis
_version_	1718403069942693888

The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis

Ejemplares similares